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particularly in the coronary circulation. We have shown previously that intrinsic smooth
muscle tone in coronary vessels in DCM is depressed, but the functional significance of
this observation in vivo is unknown.
Methods: We studied the responses of the systemic and coronary circulation to a variety
of vasodilators in conscious dogs with pacing-induced DCM (240 min-1, 29±4 days). The
dogs received graded IV infusions of the endothelium-dependent acetylcholine (ACH,
0.25-5 µg/kg, n=18), the c-GMP dependent NO-donor nitroglycerin (NTG, 30-240 µg,
n=18), the predominantly endothelium-independent adenosine (ADO, 0.5-5 µmol/kg,
n=9), the β-adrenergic c-AMP dependent agonist isoproterenol (ISO, 0.05-0.4 µg/kg,
n=14) and the calcium channel antagonist nicardipine (NIC, 0.3-10 µmol/kg, n=6) in con-
trol (C) and in severe DCM.
Results: Systemic responses were impaired to ACH but preserved to all other vasodila-
tors in DCM. However, coronary flow (CBF) and vasodilator responses (CVR) were sig-
nificantly (p< 0.05) depressed to all agonists when equivalent doses were compared.
(Peak CBF responses, C vs DCM: ACH: 221±14% vs 160±11%, NTG: 220±17% vs
138±9%, ADO: 635±74% vs 413±65%, NIC: 338±59% vs 115±23%, ISO: 219±19% vs
87±21%. Peak CVR responses, C vs DCM: ACH: -77±1% vs -69±1%, NTG: -75±1% vs -
62±2%, ADO: -88±1% vs -77±3%, NIC: -79±2% vs -63±4%, ISO: -67±2% vs -48±5%).
This generalized impairment in coronary vasodilator responses persisted after controlling
for heart rate differences or changes in mean arterial pressure.
Conclusions: In contrast to systemic vasodilator responses, coronary vasodilation in
DCM is impaired to a multitude of agonists, dependent or independent of NO or second
messenger mechanisms. This implies structural or distal signaling defects unique to the
coronary vascular smooth muscle in DCM.
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Background: Patients with peripartum cardiomyopathy (PPC) have a better prognosis
than other forms of cardiomyopathy. However, historical studies showed that 40 to 50% of
patients with PPC do not have a meaningful recovery or experienced a significant deteri-
oration in their cardiac function. These studies were done before the current era of heart
failure management. We report the University of Alabama at Birmingham’s experience
with this form of cardiomyopathy.
Methods and Results: Thirty-seven patients were referred to our program with peripar-
tum cardiomyopathy between January 1, 1990 and December 31, 2002. The data was
extracted from the clinical charts. The age at diagnosis was 28±6.6 years, and on aver-
age patients were 33 days postpartum (range 60 days pre-180 days post-partum).
Eighty-one percent were NYHA class III or IV. The mean LVEDD was 57.9±10.0 mm and
the LVEF was 23.5±11.5%. Thirty-two (87%) were treated with ACE inhibitors, 9 (25%)
with angiotensin receptor blockers and 17 (46%) with beta-blockers. In addition they were
also treated with digoxin (76%), diuretics (89%), spironolactone (33%), nitrates (6%) and
warfarin (41%).
Patients were followed for an average of 28 (range 1-94) months. Four patients were
transplanted, 1 died and 1 was lost to follow-up. The NYHA class improved significantly
(P=0.007). More importantly, the NYHA class improved in all but the patients who died or
were transplanted or lost to follow-up. Of the survivals or not transplanted or lost to fol-
low-up, 25/31 (90%) were NYHA class I-II and none was NYHA class IV. Thirty-one
patients had follow-up echocardiograms in our institution. Overall, the LVEF improved
significantly to 40.3±16.4% (p<0.001), as well as the LVEDD (52.8±8.8 mm, p=0.007).
Seventy-two percent of the patients had a significant improvement in the LVEF to > 40%,
and 42% of patients normalized their LVEF. There was no difference in NYHA class,
LVEF or transplant/death rates in patients who were treated with beta-blockers compared
to whose who were not.
Conclusion: The prognosis of PPC appears to be better than previously reported. Trans-
plantation or more invasive therapies should be reserved for those patients who fail med-
ical therapy.
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Background: Diagnosis of cardiac sarcoidosis (CS) is usually confirmed during the fol-
low-up of extra-cardiac sarcoidosis. However, the diagnosis is often difficult when CS
patients show heart failure as the first manifestation without evidence of involvement of
other organs because endomyocardial biopsy frequently fails to reveal non-caseating
epithelioid granuloma. Majority of these patients are diagnosed as idiopathic dilated car-
diomyopathy (DCM). Methods: To characterize CS patients presenting as unexplained
heart failure (CS-HF), we reviewed 30 consecutive CS patients diagnosed between 1987
and 2002 and identified 11 CS-HF patients. Clinical findings and outcome of the CS-HF
were compared to those of 123 DCM patients diagnosed at the same period. Results:
Abnormal accumulation of gallium-67 in the heart or extra-cardiac tissue was the first
clue to suspect CS in 7 of the 8 CS-HF who underwent the whole body gallium-67 scan.
Granulomas were confirmed from the heart in 5 patients, lymph nodes in 4, skin in 1 and
skeletal muscle in 1. The CS-HF showed higher incidence of female (70% vs. 22%, p<
0.001), complete atrioventricular block (70% vs. 0%, p<0.0001) and sustained ventricular
tachycardia (40% vs. 9%, p< 0.05), and lower cardiac index (2.0±0.4 l/min/m2 vs. 2.5±0.5
l/min/m2, p< 0.05) and left ventricular dimension (58±11 mm vs. 68±8 mm, p<0.05) as
compared with DCM patients. During a mean follow-up of 80 months, 6 CS-HF died sud-
denly or of refractory heart failure. Although 10 of the 11 were treated with corticoster-
oids, survival rate was significantly worse in CS-HF than DCM (40% vs. 72%, p<0.001).
Conclusions: CS-HF had different clinical features and outcomes as compared with
DCM. Understanding these features and comprehensive examinations including whole
body gallium-67 scan and biopsies from the extra-cardiac tissue are useful for the diag-
nosis of CS patients presenting as unexplained heart failure and cardiomyopathies.
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Background: In COMET carvedilol (25 mg bid) was shown to reduce mortality compared
to metoprolol (IR 50 mg bid) (512 deaths/1511 versus 600/1518, p=0.0017) in the treat-
ment of heart failure with a mean follow-up of 57.9 months. Adverse events would be
expected to reflect this advantageous outcome. The alpha-1 and beta-2-blocking effects
of carvedilol, which possibly contributed to its survival advantage, are expected to be
reflected in the adverse events profile.
Methods: 3029 patients with left ventricular systolic dysfunction and NYHA class II to IV
were randomised to double-blind study therapy. Patients were seen every four months
over a period of 47 to 71 months. Adverse events as reported by the investigator were
recorded on the case record form and analysed centrally.
Results: Of 1511 patients allocated to carvedilol 93.6% experienced an adverse event
and 73.9% a cardiovascular adverse event. Of 1518 patients allocated metoprolol the fig-
ures were 95.9% and 75.8%. Adverse event reports of sudden death (8.9% versus
12.1%), myocardial infarction (4.6% versus 6.3%), unstable angina (3.8% versus 5.1 %)
and stroke (3.5% versus 4.3%) were less common with carvedilol. Heart failure (42.6%
versus 44.9%), dyspnoea (9.7% versus 11.2%) and peripheral oedema (2.6% versus
3.7%) occurred less frequently with carvedilol. No consistent differences existed with
regard to bradycardia or heart block. Hypotension (14.2% versus 10.5%), dizziness
(12.4% versus 11.7%) and syncope 8.2% versus 6.3%) were commoner with carvedilol.
Diabetes (11.1% versus 12.5%) and hypokalaemia (2.0% versus 3.2%) were less com-
mon with carvedilol. The incidence of bronchospasm (0.7% versus 0.4%) and asthma
(0.5% versus 0.3%) was very low in both groups.
These differences do not take account of the fact that because of the greater mortality
with metoprolol more patients in the carvedilol group were available to experience
adverse events.
Conclusion: The lower number of adverse cardiovascular events with carvedilol reflects
the beneficial effect on mortality. Metabolic and haemodynamic adverse events are com-
patible with the known different properties of these two beta-blockers.
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Background: In the COMET study carvedilol (C) had a significantly greater benefit on
survival than metoprolol (M) in patients with NYHA class II-IV heart failure (HF), with a
20% reduction for cardiovascular (CV) mortality (RR 0.80 ;95% CI 0.7-0.9, p=0.0004).
Here, we report the differentiation of CV death and the possible contribution of vascular
event reduction to the beneficial effect of carvedilol.
Methods: 3029 patients with NYHA class II-IV HF, due to ischemic (51-54%) or idio-
pathic cardiomyopathy (44%) were randomized to C (n=1511) or M (n=1518) and fol-
lowed-up double-blind for 58 months. Baseline characteristics and primary outcomes
have been reported. Mode of deaths was adjudicated centrally. CV death included sud-
den, worsening HF, stroke and other CV death. Hospitalizations for myocardial infarctions
were based on pre-specified criteria. Data provided are in the intention-to-treat popula-
tion.
Results: Sudden death and death due to worsening HF were reduced in C compared to
M (RR 0.81, CI 0.68-0.97 p=0.02, and RR 0.83, CI 0.67-1.02 p=0.07 respectively).
Myocardial infarctions were reported in 69 C and 94 M patients (RR 0.71, CI 0.52-0.97,
p=0.03). Of these, 21 and 36 lead to death in C and M respectively. CV death or non-fatal
myocardial infarction combined were reduced by 19% in C, compared to M (RR 0.81, CI
0.72-0.92, p=0.0007). A stroke occurred in 65 C and 80 M patients (RR 0.79, CI 0.57-
1.10). C significantly reduced stroke deaths, 13 C versus 38 M (RR 0.33, CI 0.18-0.62,
